Satellos Bioscience Inc. (TSX:MSCL)
9.50
-0.40 (-4.04%)
Oct 14, 2026, 3:56 PM EST
Satellos Bioscience Employees
As of December 31, 2025, Satellos Bioscience had 21 total employees, including 18 full-time and 3 part-time employees. The number of employees increased by 4 or 23.53% compared to the previous year. That makes Satellos Bioscience the 38,235th largest employer in the world and 662nd in Canada.
Employees
21
Change (1Y)
4
Growth (1Y)
23.53%
Revenue / Employee
n/a
Profits / Employee
-2.46M CAD
Market Cap
201.56M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | 4 | 23.53% | 18 | 3 |
| Dec 31, 2024 | 17 | 1 | 6.25% | 14 | 3 |
| Dec 31, 2023 | 16 | - | - | 4 | 12 |
Related Stocks
| Company Name | Employees |
|---|---|
| Eupraxia Pharmaceuticals | 49 |
| Bright Minds Biosciences | 26 |
| BriaCell Therapeutics | 16 |
| Sernova Biotherapeutics | 8 |
| Helix BioPharma | 7 |
Satellos Bioscience News
- 7 days ago - Craig-Hallum initiates Satellos with a Buy ahead of BASECAMP data - TheFly
- 7 days ago - Satellos initiated with a Buy at Craig-Hallum - TheFly
- 10 days ago - Satellos granted composition of matter patent for forazapadin - TheFly
- 10 days ago - Satellos Granted Composition of Matter Patent for Forazapadin - Financial Post
- 10 days ago - Satellos Granted Composition of Matter Patent for Forazapadin - GlobeNewsWire
- 15 days ago - Satellos Completes Enrollment In Phase 2 Forazapadin Trial For DMD - Nasdaq
- 15 days ago - Satellos announces enrollment completed for BASECAMP - TheFly
- 15 days ago - Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy - Financial Post